NASDAQ : DYN
Dyne Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 16.69 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 91.13M | 69.85M | 62.48M | 31.40M | 28.20M | 28.72M |
| Research & Development | 445.82M | 398.33M | 281.41M | 210.76M | 142.76M | 121.31M |
| Operating Expenses | 536.96M | 468.18M | 343.89M | 242.16M | 170.96M | 150.03M |
| Operating Income | -536.96M | -468.18M | -343.89M | -242.16M | -170.96M | -150.03M |
| Interest Expense | -14.89M | -6.19M | ||||
| Interest & Investment Income | 32.68M | 29.86M | 26.92M | 7.64M | 2.92M | 742.00K |
| Currency Exchange Gain (Loss) | -227.00K | -1.73M | -489.00K | -1.39M | -20.00K | |
| Other Non Operating Income (Expenses) | -32.00K | |||||
| EBT Excluding Unusual Items | -519.43M | -446.24M | -317.45M | -235.91M | -168.06M | -149.28M |
| Gain (Loss) on Sale of Investments | 30.00K | 30.00K | 35.00K | -23.00K | -34.00K | -8.00K |
| Pretax Income | -519.40M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
| Net Income | -519.40M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
| Net Income to Common | -519.40M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
| Shares Outstanding (Basic) | 155.11M | 128.44M | 94.14M | 59.68M | 51.98M | 50.90M |
| Shares Outstanding (Diluted) | 155.11M | 128.44M | 94.14M | 59.68M | 51.98M | 50.90M |
| EPS (Basic) | -3.35 | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 |
| EPS (Diluted) | -3.35 | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 |
| Free Cash Flow | -499.22M | -423.92M | -294.75M | -188.89M | -156.71M | -123.18M |
| Free Cash Flow Per Share | -3.22 | -3.30 | -3.13 | -3.17 | -3.02 | -2.42 |
| EBITDA | -534.80M | -466.13M | -342.21M | -240.49M | -169.28M | -148.94M |
| D&A For EBITDA | 2.15M | 2.05M | 1.67M | 1.67M | 1.68M | 1.09M |
| EBIT | -536.96M | -468.18M | -343.89M | -242.16M | -170.96M | -150.03M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 676.11M | 893.37M | 435.45M | 121.63M | 172.15M | 200.82M |
| Short-Term Investments | 222.36M | 217.19M | 206.82M | 1.47M | 83.86M | 175.75M |
| Cash & Short-Term Investments | 898.48M | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Prepaid Expenses | 39.41M | 16.02M | 17.01M | 6.28M | 9.58M | 5.44M |
| Restricted Cash | 383.00K | |||||
| Total Current Assets | 937.89M | 1.13B | 659.28M | 129.38M | 265.59M | 382.39M |
| Property, Plant & Equipment | 44.81M | 44.77M | 30.01M | 33.39M | 38.41M | 40.96M |
| Long-Term Deferred Charges | 500.00K | 500.00K | ||||
| Other Long-Term Assets | 10.81M | 15.10M | 1.94M | 2.31M | 2.32M | 2.31M |
| Total Assets | 994.01M | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Accounts Payable | 12.15M | 8.08M | 6.56M | 22.94M | 5.26M | 4.03M |
| Accrued Expenses | 46.36M | 37.55M | 30.85M | 23.44M | 18.22M | 20.74M |
| Current Portion of Leases | 5.37M | 5.00M | 4.85M | 4.72M | 4.61M | 3.89M |
| Other Current Liabilities | 1.00K | 62.00K | ||||
| Total Current Liabilities | 78.03M | 50.62M | 42.26M | 51.09M | 28.09M | 28.72M |
| Long-Term Debt | 199.33M | 148.92M | ||||
| Long-Term Leases | 14.51M | 15.28M | 19.14M | 22.70M | 25.87M | 28.74M |
| Total Liabilities | 291.86M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Common Stock | 16.00K | 16.00K | 10.00K | 6.00K | 6.00K | 6.00K |
| Additional Paid-In Capital | 2.40B | 2.37B | 1.58B | 723.80M | 649.50M | 596.93M |
| Retained Earnings | -1.70B | -1.40B | -949.93M | -632.51M | -396.57M | -228.47M |
| Comprehensive Income & Other | -353.00K | 475.00K | 6.00K | -571.00K | -269.00K | |
| Total Common Equity | 702.15M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
| Shareholders' Equity | 702.15M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
| Total Liabilities & Equity | 994.01M | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Total Debt | 233.35M | 169.20M | 23.99M | 27.41M | 30.48M | 32.64M |
| Net Cash (Debt) | 665.12M | 941.36M | 618.28M | 95.69M | 225.53M | 343.94M |
| Net Cash Per Share | 4.29 | 7.33 | 6.57 | 1.60 | 4.34 | 6.76 |
| Filing Date Shares Outstanding | 186.75M | 165.03M | 113.12M | 81.96M | 56.34M | 51.60M |
| Total Common Shares Outstanding | 165.67M | 164.95M | 102.32M | 61.47M | 55.63M | 51.53M |
| Working Capital | 859.86M | 1.08B | 617.02M | 78.28M | 237.51M | 353.67M |
| Book Value Per Share | 4.24 | 5.89 | 6.16 | 1.49 | 4.54 | 7.15 |
| Tangible Book Value | 702.15M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
| Tangible Book Value Per Share | 4.24 | 5.89 | 6.16 | 1.49 | 4.54 | 7.15 |
| Machinery | 15.50M | 13.45M | 11.55M | 9.64M | 8.67M | 5.20M |
| Construction In Progress | 18.79M | 19.30M | 619.00K | 431.00K | 906.00K | 1.46M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -519.40M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
| Depreciation & Amortization | 2.15M | 2.05M | 1.67M | 1.67M | 1.68M | 1.09M |
| Loss (Gain) From Sale of Assets | 30.00K | 95.00K | 72.00K | 118.00K | ||
| Loss (Gain) From Sale of Investments | -1.31M | -1.86M | -3.64M | -1.08M | 1.31M | 2.59M |
| Stock-Based Compensation | 50.37M | 45.85M | 45.86M | 19.97M | 15.18M | 17.54M |
| Other Operating Activities | 620.00K | 281.00K | 570.00K | 788.00K | 1.66M | -746.00K |
| Change in Accounts Payable | 23.17M | 8.25M | -8.96M | 22.97M | -1.24M | 13.70M |
| Change in Other Net Operating Assets | -33.43M | -11.65M | -10.54M | 3.34M | -4.14M | -4.45M |
| Operating Cash Flow | -477.82M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Capital Expenditures | -21.40M | -20.71M | -2.38M | -729.00K | -3.07M | -3.62M |
| Investment in Securities | -22.77M | -8.04M | -201.70M | 84.04M | 90.27M | -134.27M |
| Investing Cash Flow | -44.17M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Long-Term Debt Issued | 148.26M | |||||
| Net Debt Issued (Repaid) | 113.03M | 148.26M | ||||
| Issuance of Common Stock | 601.44M | 742.61M | 809.89M | 54.32M | 37.39M | 157.82M |
| Other Financing Activities | -1.01M | -558.00K | ||||
| Financing Cash Flow | 713.47M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
| Net Cash Flow | 191.48M | 458.35M | 313.45M | -50.52M | -29.05M | -99.63M |
| Free Cash Flow | -499.22M | -423.92M | -294.75M | -188.89M | -156.71M | -123.18M |
| Free Cash Flow Per Share | -3.22 | -3.30 | -3.13 | -3.17 | -3.02 | -2.42 |
| Levered Free Cash Flow | -317.14M | -260.09M | -189.47M | -104.23M | -98.17M | -66.94M |
| Unlevered Free Cash Flow | -307.83M | -256.22M | -189.47M | -104.23M | -98.17M | -66.94M |
| Cash Interest Paid | 15.80M | 4.34M | ||||
| Change in Working Capital | -10.27M | -3.40M | -19.49M | 26.31M | -5.38M | 9.26M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.14B | 3.22B | 2.40B | 816.30M | 604.12M | 606.03M |
| Enterprise Value | 2.47B | 2.55B | 1.70B | 686.70M | 387.17M | 232.51M |
| Last Close Price | 16.69 | 19.56 | 23.56 | 13.30 | 11.59 | 11.89 |
| PB Ratio | 3.94 | 3.31 | 3.81 | 8.94 | 2.39 | 1.65 |
| P/TBV Ratio | 4.56 | 3.31 | 3.81 | 8.94 | 2.39 | 1.65 |
| Debt / Equity Ratio | 0.33 | 0.17 | 0.04 | 0.30 | 0.12 | 0.09 |
| Net Debt / Equity Ratio | -0.95 | -0.97 | -0.98 | -1.05 | -0.89 | -0.93 |
| Net Debt / EBITDA Ratio | 1.24 | 2.02 | 1.81 | 0.40 | 1.33 | 2.31 |
| Net Debt / FCF Ratio | 1.33 | 2.22 | 2.10 | 0.51 | 1.44 | 2.79 |
| Quick Ratio | 11.52 | 21.94 | 15.20 | 2.41 | 9.12 | 13.11 |
| Current Ratio | 12.02 | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 |
| Return on Equity (ROE) | -81.56% | -55.71% | -88.03% | -137.31% | -54.18% | -42.02% |
| Return on Assets (ROA) | -38.95% | -31.16% | -50.20% | -64.21% | -29.20% | -24.07% |
| Return on Capital Employed (ROCE) | -58.60% | -41.20% | -53.00% | -212.40% | -61.40% | -37.80% |
| Earnings Yield | -19.93% | -13.86% | -13.24% | -28.90% | -27.82% | -24.63% |
| FCF Yield | -15.59% | -13.16% | -12.29% | -23.14% | -25.94% | -20.33% |
| Buyback Yield / Dilution | -45.37% | -36.43% | -57.74% | -14.83% | -2.12% | -253.54% |